![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, October 10, 2006 9:12:24 AM
1) The clinical hold on CX-717 is partially lifted, but only for a specified/limited dose range. Presumably this means the lower doses. It might also mean shorter duration of dosing. Once the new 3 month tox data is completed and the results analyzed, then the dosing restrictions could be removed by the FDA.
2) The AD PET scan trial can resume (the only clinical trial that was still underway at the time the clinical hold was put into effect). The press release doesn't say anything about the initiation of new trials (presumably this would be OK, but subject to the dosing restrictions).
3) An ADHD Phase 2b of the type Cortex or a BP would want to run (high dosing levels, longer duration) probably can't be initiated until the new 3 month tox study is completed and the dosing restrictions are removed.
4) BP negotiations will resume but will probably not be consumated until after the FDA analyzes the new 3 month tox data and lifts the dosing restrictions.
A few other thoughts -
a) Based on yesterday's volume, we might (hopefully) be seeing some significant warrant share activity. Proceeds from those warrants would help replenish Cortex's cash, which is otherwise estimated at only $8-10 mil by year end. Warrant proceeds would reduce the need for a Q4 financing, though we might get one anyway.
b) The partial lifting of the hold (with dosing restrictions) should delay consumating the BP deal, and this delay could subsequently delay completion of the non-Ampakine in-licensing. This could be a problem if other companies are also interested in acquiring that program and have ready cash.
c) I don't remember Dr. Stoll publicly saying that they were repeating the 3 month tox study in 2 species (unless I missed it). All along we had been under the impression that the problem/deficiency was only in the short term acute studies. The FDA apparently didn't request the new 3 month tox studies, but these were probably recommended by the consultants Cortex hired, just in case. Hiring those guys was a smart move.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM